FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS

Eli Lilly and Company (NYSE:LLY) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 9, the US FDA approved a new maintenance dosing regimen for Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), allowing adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every 8 weeks. This approval makes EBGLYSS the only treatment option that can be managed with as few as six maintenance injections per year without the requirement of concomitant prescription topicals.

This dosing update is based on longitudinal exposure-response modeling and data from the Phase 3 ADjoin long-term extension trial. In the 32-week extension study, the drug showed durable disease control without any new safety signals or patient discontinuations due to adverse events, further establishing its clinical profile for long-term use.

Management noted that this regimen provides significant flexibility for patients, aiming to reduce the burden of daily symptom management and frequent injections. The most commonly reported side effects remain consistent with the existing profile, including conjunctivitis, injection site reactions, and herpes zoster.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.